IFRX stock gains 8% on EC nod for Gohibic, under exceptional circumstances, to treat adult patients with COVID-19-induced ...

Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on IFRX stock, giving a Buy rating yesterday.Stay Ahead of the ...

InflaRx (IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients ...

H.C. Wainwright analyst Edward White reiterated a Buy rating on InflaRx (IFRX – Research Report) today and set a price target of $8.00.Stay ...

H.C. Wainwright reaffirmed its Buy rating and $8.00 price target for InflaRx NV (NASDAQ:IFRX), following the European ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.

After hours: 7:26:26 p.m. EST Loading Chart for XERS ...

After hours: January 14 at 4:42:21 p.m. EST ...